000095052 001__ 95052
000095052 005__ 20210902121808.0
000095052 0247_ $$2doi$$a10.3390/ijms21165779
000095052 0248_ $$2sideral$$a119002
000095052 037__ $$aART-2020-119002
000095052 041__ $$aeng
000095052 100__ $$0(orcid)0000-0001-9773-7460$$aGuijarro, Isabel M.$$uUniversidad de Zaragoza
000095052 245__ $$aNeuroimmune Response in Natural Preclinical Scrapie after Dexamethasone Treatment
000095052 260__ $$c2020
000095052 5060_ $$aAccess copy available to the general public$$fUnrestricted
000095052 5203_ $$aA recently published report on chronic dexamethasone treatment for natural scrapie supported the hypothesis of the potential failure of astroglia in the advanced stage of disease. Herein, we aimed to extend the aforementioned study on the effect of this anti-inflammatory therapy to the initial phase of scrapie, with the aim of elucidating the natural neuroinflammatory process occurring in this neurodegenerative disorder. The administration of this glucocorticoid resulted in an outstanding reduction in vacuolation and aberrant protein deposition (nearly null), and an increase in glial activation. Furthermore, evident suppression of IL-1R and IL-6 and the exacerbation of IL-1α, IL-2R, IL-10R and IFNγR were also demonstrated. Consequently, the early stage of the disease is characterized by an intact neuroglial response similar to that of healthy individuals attempting to re-establish homeostasis. A complex network of neuroinflammatory markers is involved from the very early stages of this prion disease, which probably becomes impaired in the more advanced stages. The in vivo animal model used herein provides essential observations on the pathogenesis of natural scrapie, as well as the possibility of establishing neuroglia as potential target cells for anti-inflammatory therapy.
000095052 536__ $$9info:eu-repo/grantAgreement/ES/MEC/FPU15-03524$$9info:eu-repo/grantAgreement/EUR/INTERREG-POCTEFA/EFA-148-16 REDPRION
000095052 540__ $$9info:eu-repo/semantics/openAccess$$aby$$uhttp://creativecommons.org/licenses/by/3.0/es/
000095052 590__ $$a5.923$$b2020
000095052 591__ $$aBIOCHEMISTRY & MOLECULAR BIOLOGY$$b67 / 297 = 0.226$$c2020$$dQ1$$eT1
000095052 591__ $$aCHEMISTRY, MULTIDISCIPLINARY$$b49 / 178 = 0.275$$c2020$$dQ2$$eT1
000095052 592__ $$a1.455$$b2020
000095052 593__ $$aCatalysis$$c2020$$dQ1
000095052 593__ $$aComputer Science Applications$$c2020$$dQ1
000095052 593__ $$aInorganic Chemistry$$c2020$$dQ1
000095052 593__ $$aSpectroscopy$$c2020$$dQ1
000095052 593__ $$aMolecular Biology$$c2020$$dQ1
000095052 593__ $$aOrganic Chemistry$$c2020$$dQ1
000095052 593__ $$aPhysical and Theoretical Chemistry$$c2020$$dQ1
000095052 593__ $$aMedicine (miscellaneous)$$c2020$$dQ1
000095052 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000095052 700__ $$0(orcid)0000-0001-8385-0219$$aGarcés, Moisés
000095052 700__ $$0(orcid)0000-0002-1590-3347$$aMarín, Belén$$uUniversidad de Zaragoza
000095052 700__ $$0(orcid)0000-0001-9075-2764$$aOtero, Alicia$$uUniversidad de Zaragoza
000095052 700__ $$0(orcid)0000-0002-7037-6316$$aBarrio, Tomás
000095052 700__ $$0(orcid)0000-0002-7173-7216$$aBadiola, Juan J.$$uUniversidad de Zaragoza
000095052 700__ $$0(orcid)0000-0002-2787-9671$$aMonzón, Marta$$uUniversidad de Zaragoza
000095052 7102_ $$11009$$2773$$aUniversidad de Zaragoza$$bDpto. Patología Animal$$cÁrea Sanidad Animal
000095052 7102_ $$11003$$2443$$aUniversidad de Zaragoza$$bDpto. Anatom.Histolog.Humanas$$cArea Histología
000095052 773__ $$g21, 16 (2020), 5779 [17 pp.]$$pInt. j. mol. sci.$$tInternational Journal of Molecular Sciences$$x1661-6596
000095052 8564_ $$s6451324$$uhttps://zaguan.unizar.es/record/95052/files/texto_completo.pdf$$yVersión publicada
000095052 8564_ $$s467702$$uhttps://zaguan.unizar.es/record/95052/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000095052 909CO $$ooai:zaguan.unizar.es:95052$$particulos$$pdriver
000095052 951__ $$a2021-09-02-09:59:18
000095052 980__ $$aARTICLE